SCHEMBL23313191

SCHEMBL23313191

CC(C)(C)C(=O)c1cc(Cl)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
LMNA P02545 3/20 0.55
HTT P42858 3/20 0.55
KCNH2 Q12809 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
P2RX1 P51575 9/20 0.52
KCNMA1 Q12791 1/20 0.50
TMPRSS4 Q9NRS4 7/20 0.49
P2RX4 Q99571 5/20 0.49
P2RX7 Q99572 5/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
IKBKB O14920 1/20 0.49
CHUK O15111 1/20 0.49
KDR P35968 1/20 0.49
FLT3 P36888 1/20 0.49
MYLK Q15746 1/20 0.49
MAP4K5 Q9Y4K4 1/20 0.49
MAPT P10636 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10574930 0.87 CA1 (0.58) CA1CA2LMNAHTTKCNH2
SCHEMBL28475965 0.80 CA12 (0.57) CA1CA2LMNAHTTP2RX1
SCHEMBL13151996 0.79 RECQL (0.53) LMNAHTTKCNH2SMN1; SMN2KMT2A
SCHEMBL12532565 0.78 SMN1; SMN2 (0.59) HTTSMN1; SMN2MEN1KMT2AKDR
SCHEMBL26054350 0.78 CSNK2A1 (0.62) LMNAHTTSMN1; SMN2P2RX1TMPRSS4
SCHEMBL20968011 0.78 HSP90AA1 (0.60) LMNAHTTKCNH2SMN1; SMN2P2RX1
SCHEMBL28019535 0.78 KDM4E (0.53) CA1CA2LMNAHTTKCNH2
SCHEMBL218964 0.78 CA1 (0.67) CA1CA2LMNAHTTKCNH2
SCHEMBL6966672 0.77 CA1 (0.72) CA1CA2LMNAHTTSMN1; SMN2
SCHEMBL23313017 0.77 P2RX1 (0.50) CA1CA2LMNAHTTP2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10995061-B2 SPAK kinase inhibitors as neuroprotective agents UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2021-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10995061-B2 SPAK kinase inhibitors as neuroprotective agents SBK1, DAPK2, SPAST CA1 1530/4885CA2 1302/4885LMNA 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.